Below are the most recent publications written about "Ribavirin" by people in Profiles.
-
Malaguarnera G, Bertino G, Chisari G, Motta M, Vecchio M, Vacante M, Caraci F, Greco C, Drago F, Nunnari G, Malaguarnera M. Silybin supplementation during HCV therapy with pegylated interferon-a plus ribavirin reduces depression and anxiety and increases work ability. BMC Psychiatry. 2016 Nov 15; 16(1):398.
-
Harrington PR, Fleischer R, Connelly SM, Lewis LL, Murray J. Reply to Merli et al. Clin Infect Dis. 2016 Feb 15; 62(4):528-9.
-
Harrington PR, Fleischer R, Connelly SM, Lewis LL, Murray J. Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens. Clin Infect Dis. 2015 Sep 15; 61(6):974-7.
-
Dvory-Sobol H, Voitenleitner C, Mabery E, Skurnac T, Lawitz EJ, McHutchison J, Svarovskaia ES, Delaney W, Miller MD, Mo H. Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother. 2014 Nov; 58(11):6599-606.
-
Pfeffer LM, Li K, Fleckenstein JF, Marion TN, Diament J, Yang CH, Pfeffer SR, Fan M, Handorf E, Handorf CR. An interferon response gene signature is associated with the therapeutic response of hepatitis C patients. PLoS One. 2014; 9(8):e104202.
-
Cacopardo B, Benanti F, Pinzone MR, Nunnari G. Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature. BMC Res Notes. 2013 Oct 30; 6:437.
-
Yang H, Robinson M, Corsa AC, Peng B, Cheng G, Tian Y, Wang Y, Pakdaman R, Shen M, Qi X, Mo H, Tay C, Krawczyk S, Sheng XC, Kim CU, Yang C, Delaney WE. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Antimicrob Agents Chemother. 2014; 58(2):647-53.
-
Funk EK, Shaffer A, Shivakumar B, Sneller M, Polis MA, Masur H, Heytens L, Nelson A, Kwan R, Kottilil S, Kohli A. Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. AIDS Res Hum Retroviruses. 2013 Sep; 29(9):1190-4.
-
Cacopardo B, Pinzone MR, Nunnari G. [Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review]. Infez Med. 2013 Mar; 21(1):40-44.
-
Osinusi A, Naggie S, Poonia S, Trippler M, Hu Z, Funk E, Schlaak J, Fishbein D, Masur H, Polis M, Kottilil S. ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. J Med Virol. 2012 Jul; 84(7):1106-14.